Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
0.824
-0.047 (-5.37%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Immuron Employees
Immuron had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$712,477
Profits / Employee
-$442,735
Market Cap
7.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 1 | 16.67% |
| Jun 30, 2023 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| FibroBiologics | 15 |
| TransCode Therapeutics | 12 |
| MetaVia | 8 |
| Indaptus Therapeutics | 5 |
| Can-Fite BioPharma | 5 |
| Acurx Pharmaceuticals | 4 |
| Silo Pharma | 3 |
| Addex Therapeutics | 2 |
IMRN News
- 6 days ago - Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00 - Accesswire
- 11 days ago - Immuron Double Digit 3Q Sales Growth - GlobeNewsWire
- 7 weeks ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 7 weeks ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 3 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 3 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire
- 5 months ago - Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes - GuruFocus
- 6 months ago - Immuron (IMRN) Secures FDA Approval for Phase 2 Trial of IMM-529 - GuruFocus